sb 203580 has been researched along with Neuroendocrine Tumors in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blanc, M; Cordier-Bussat, M; Couderc, C; Gouysse, G; Nejjari, M; Roche, C; Scoazec, JY; Vercherat, C; Villaume, K; Walter, T | 1 |
1 other study(ies) available for sb 203580 and Neuroendocrine Tumors
| Article | Year |
|---|---|
VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway.
Topics: Animals; Cell Line, Tumor; Cell Survival; Chromones; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Hypoxia-Inducible Factor 1, alpha Subunit; Imidazoles; Insulin; Insulin Secretion; Intracellular Signaling Peptides and Proteins; MAP Kinase Kinase 1; Mice; Morpholines; Neuroendocrine Tumors; Octreotide; p38 Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Rats; Sirolimus; Somatostatin; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |